TY - JOUR
T1 - Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins
AU - Nyakatura, Elisabeth K.
AU - Zak, Samantha E.
AU - Wec, Anna Z.
AU - Hofmann, Daniel
AU - Shulenin, Sergey
AU - Bakken, R. R.
AU - Javad Aman, M.
AU - Chandran, Kartik
AU - Dye, John M.
AU - Lai, Jonathan R.
N1 - Publisher Copyright:
© 2018 American Society for Biochemistry and Molecular Biology Inc. All Rights Reserved.
PY - 2018/4/20
Y1 - 2018/4/20
N2 - Filoviruses (family Filoviridae) include five ebolaviruses and Marburg virus. These pathogens cause a rapidly progressing and severe viral disease with high mortality rates (generally 30 -90%). Outbreaks of filovirus disease are sporadic and, until recently, were limited to less than 500 cases. However, the 2013-2016 epidemic in western Africa, caused by Ebola virus (EBOV), illustrated the potential of filovirus outbreaks to escalate to a much larger scale (over 28,000 suspected cases). mAbs against the envelope glycoprotein represent a promising therapeutic platform for managing filovirus infections. However, mAbs that exhibit neutralization or protective properties against multiple filoviruses are rare. Here we examined a panel of engineered bi- and trispecific antibodies, in which variable domains of mAbs that target epitopes from multiple filoviruses were combined, for their capacity to neutralize viral infection across filovirus species. We found that bispecific combinations targeting EBOV and Sudan virus (another ebolavirus), provide potent cross-neutralization and protection in mice. Furthermore, trispecific combinations, targeting EBOV, Sudan virus, and Marburg virus, exhibited strong neutralization potential against all three viruses. These results provide important insights into multispecific antibody engineering against filoviruses and will inform future immunotherapeutic discoveries.
AB - Filoviruses (family Filoviridae) include five ebolaviruses and Marburg virus. These pathogens cause a rapidly progressing and severe viral disease with high mortality rates (generally 30 -90%). Outbreaks of filovirus disease are sporadic and, until recently, were limited to less than 500 cases. However, the 2013-2016 epidemic in western Africa, caused by Ebola virus (EBOV), illustrated the potential of filovirus outbreaks to escalate to a much larger scale (over 28,000 suspected cases). mAbs against the envelope glycoprotein represent a promising therapeutic platform for managing filovirus infections. However, mAbs that exhibit neutralization or protective properties against multiple filoviruses are rare. Here we examined a panel of engineered bi- and trispecific antibodies, in which variable domains of mAbs that target epitopes from multiple filoviruses were combined, for their capacity to neutralize viral infection across filovirus species. We found that bispecific combinations targeting EBOV and Sudan virus (another ebolavirus), provide potent cross-neutralization and protection in mice. Furthermore, trispecific combinations, targeting EBOV, Sudan virus, and Marburg virus, exhibited strong neutralization potential against all three viruses. These results provide important insights into multispecific antibody engineering against filoviruses and will inform future immunotherapeutic discoveries.
UR - http://www.scopus.com/inward/record.url?scp=85045844693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045844693&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA117.001627
DO - 10.1074/jbc.RA117.001627
M3 - Article
C2 - 29500195
AN - SCOPUS:85045844693
SN - 0021-9258
VL - 293
SP - 6201
EP - 6211
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 16
ER -